Collegium Pharmaceutical, Inc. (COLL): Rubric Capital Management LP reduced its stake -1.33M shares
Rubric Capital Management LP reduced its stake in Collegium Pharmaceutical, Inc., per its Q4 2025 13F.
- 1.5M
- Shares reported · -1.33M vs prior quarter
- 0.83%
- Disclosed portfolio weight
- $69.3M
- Reported value
- Holdings as of
- Dec 31, 2025
- Filed
- Feb 13, 2026
What stands out in this filing
- 2,826,498 shares in Q3 2025, 1,496,436 now (−47.1% in share count).
- Reported at $69.3M, 0.83% of the portfolio value in this 13F filing.
- 6 other tracked managers reported the same kind of change for Q4 2025.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
What came next
- Feb 26, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
- Mar 3, 2026Insider · 1 personInsiders: 2 sales (~$2.0M)
- Mar 9, 2026InsiderOfficer sold ~$228K of COLL shares in the open market
- Mar 18, 2026InsiderOfficer sold ~$488K of COLL shares in the open market
- Mar 19, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
- Apr 2, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 6, 2026, the board of directors (“Board”) of Collegium Pharmaceutical, Inc. (the “Company”) approved the nomination of Michael Donovan to stand for election at the Company’s 2026 Annual Meeting of Shareholders (the “Annual Meeting”).”
- May 7, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
- May 11, 2026InsiderDirector sold ~$323K of COLL shares in the open market
- May 12, 2026Company filing · Form 8-K · Acquisition or sale, Executive changeCompleted buying or selling a business or assets, and changed a top executive or board member (and 1 more item)“On May 11, 2026, the Company’s board of directors adopted the Company’s 2026 Inducement Plan (the “ Inducement Plan ”), pursuant to which the Company may grant non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, and dividend equivalent rights with respect to an aggregate of 325,000 shares of the Company’s common stock, par value $0.001…”
- May 13, 2026InsiderDirector sold ~$162K of COLL shares in the open market
- May 15, 2026InsiderDirector sold ~$143K of COLL shares in the open market
- May 18, 2026InsiderDirector sold ~$681 of COLL shares in the open market
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Collegium Pharmaceutical, Inc.
For Collegium Pharmaceutical, Inc., OQRO holds 3 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its COLL page.
How this filing works
Explore the data
Common questions
What does this filing report about Collegium Pharmaceutical, Inc. (COLL) stock?
Rubric Capital Management LP reduced its stake in Collegium Pharmaceutical, Inc., per its Q4 2025 13F. Now 1.5M shares, $69.3M reported value, 0.83% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Dec 31, 2025. Filed: Feb 13, 2026.
What stands out in this filing?
2,826,498 shares in Q3 2025, 1,496,436 now (−47.1% in share count). Reported at $69.3M, 0.83% of the portfolio value in this 13F filing. 6 other tracked managers reported the same kind of change for Q4 2025.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Collegium Pharmaceutical, Inc. recently?
For Collegium Pharmaceutical, Inc., OQRO holds 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the COLL page.
Does this mean COLL stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Collegium Pharmaceutical, Inc.
- SEC Schedule 13GNov 16, 2026
- SEC Schedule 13GNov 16, 2026
- SEC Schedule 13GOct 29, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 4May 20, 2026
- SEC Form 4May 18, 2026
Everything OQRO holds on this company is on its COLL page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data